Pomdoctor Limited (POM) 株式分析

企業概要

Pomdoctor Limited operates through its subsidiaries to provide an online B2C portal for the sale of pharmaceutical products, while simultaneously developing a specialized online medical services platform dedicated to chronic disease management within the Chinese market. The company focuses on chronic disease management and pharmaceutical services, offering a comprehensive platform that connects patients with necessary medical treatments and information. It operates within the Healthcare sector, specifically classified under the industry of Pharmaceutical Retailers, which implies a business model reliant on the distribution and sale of medical goods alongside service-oriented digital solutions. The company maintains a market capitalization of $29.50M and generated annual revenue of $366.86M, employing a workforce of 156 individuals to execute its operations. These financial figures indicate that despite a relatively small market capitalization, the entity commands significant revenue throughput, suggesting a high-volume business model typical of retail operations where margins may be compressed but sales volume is substantial.

財務健全性

Pomdoctor Limited reported a total revenue of $366.86M for the trailing twelve months, yet recorded a net income loss of $-148,901,728 and an EBITDA loss of $-25,949,008, revealing a cost structure where operating expenses significantly outpace gross profits. The company's free cash flow stood at $-12,435,489, which indicates a lack of financial flexibility as the firm is currently burning cash rather than generating liquidity for reinvestment or debt repayment. The gross margin is 14.1%, reflecting the standard profitability after direct costs of goods sold in the pharmaceutical retail sector, while the operating margin of -6.5% and profit margin of -40.6% highlight substantial overhead burdens and low net profitability relative to sales. In terms of leverage, the company holds $5.75M in cash against $456.02M in total debt, resulting in a negative price-to-book ratio of -0.03 and an EV/EBITDA of -87.40, which characterizes a highly leveraged balance sheet where liabilities far exceed liquid assets. The current ratio is 0.17, a metric that signals severe short-term liquidity constraints as current assets are insufficient to cover current liabilities without external financing or asset liquidation. Return on Equity is listed as N/A due to the negative equity position, while the Return on Assets is -32.6%, indicating that the company's asset base is currently generating negative returns rather than contributing to shareholder value.

バリュエーション評価

The trailing twelve-month P/E ratio and forward P/E ratio are both listed as N/A due to the company's negative earnings, which prevents the calculation of traditional earnings-based valuation multiples that typically guide investor expectations. The price-to-book ratio is recorded at -0.03, indicating that the market valuations the company at a level below its book value, a situation often seen in distressed entities or those with heavy debt loads. Alternative valuation metrics such as the price-to-sales ratio of 0.08 and an EV/EBITDA of -87.40 suggest that the stock is priced at a negligible fraction of its sales volume, reflecting deep market skepticism regarding future profitability and cash generation capabilities. Over the past year, the stock price has fluctuated between a 52-week low of $0.19 and a 52-week high of $6.43, with the current trading price situated well below the 52-week high, illustrating the significant volatility and downward pressure the stock has faced. The beta value is listed as N/A, meaning that the historical volatility relative to the broader market index cannot be quantified from the available data, though the wide range between the 52-week high and low implies high price instability.

Growth & Income

Pomdoctor Limited experienced a revenue growth rate of 16.2% year-over-year, while earnings growth is listed as N/A due to the company's continued net losses, implying that revenue expansion has not yet translated into improved profitability or earnings per share growth. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which indicates that the firm retains all its earnings—or in this case, all its losses—to fund operations rather than distributing cash to shareholders. This non-dividend profile aligns with the company's financial position where cash reserves are limited to $5.75M and are likely being utilized to service its $456.02M in debt obligations and cover operational deficits. The overall growth and income profile is characterized by strong top-line revenue expansion offset by persistent structural losses and a complete lack of income generation for investors in the form of dividends or earnings accretion.